Bristol Myers Squibb (NYSE:BMY) Sets New 52-Week High – What’s Next?

Posted by Stanley Muller on Aug 19th, 2026

Shares of Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $68.19 and last traded at $68.2230, with a volume of 1320328 shares changing hands. The stock had previously closed at $66.05.

Analyst Ratings Changes

Several research analysts have issued reports on BMY shares. Royal Bank Of Canada raised their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Wells Fargo & Company set a $65.00 target price on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a research note on Friday, July 31st. TD Cowen started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating on the stock. Citigroup restated a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Get Our Latest Report on Bristol Myers Squibb

Bristol Myers Squibb Price Performance

The stock has a fifty day moving average of $59.94 and a two-hundred day moving average of $59.14. The stock has a market cap of $138.44 billion, a price-to-earnings ratio of 14.92, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Archer Investment Corp acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $1,399,000. Kingsview Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $2,598,000. Beacon Pointe Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $13,408,000. Kimelman & Baird LLC purchased a new position in Bristol Myers Squibb in the 2nd quarter valued at approximately $895,000. Finally, 49 Wealth Management LLC acquired a new position in Bristol Myers Squibb during the second quarter worth $210,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

About Bristol Myers Squibb

(Get Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.